-
Tytuł:
-
Complementemia in pregnancies with antiphospholipid syndrome.
-
Autorzy:
-
Tabacco S; Department of Gynaecology Obstetrics and Urology, 'Sapienza' University of Rome, Rome, Italy.
Giannini A; Department of Gynaecology Obstetrics and Urology, 'Sapienza' University of Rome, Rome, Italy.
Garufi C; Lupus Clinic, 'Sapienza' University of Rome, Rome, Italy.
Botta A; UOC di Patologia Ostetrica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
Salvi S; UOC di Patologia Ostetrica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
Del Sordo G; Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Roma, Italia.
Benedetti Panici P; Department of Gynaecology Obstetrics and Urology, 'Sapienza' University of Rome, Rome, Italy.
Lanzone A; UOC di Patologia Ostetrica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.; Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Roma, Italia.
De Carolis S; UOC di Patologia Ostetrica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.; Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Roma, Italia.
-
Źródło:
-
Lupus [Lupus] 2019 Nov; Vol. 28 (13), pp. 1503-1509. Date of Electronic Publication: 2019 Oct 17.
-
Typ publikacji:
-
Editorial
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : SAGE Publications
Original Publication: Houndmills, Basingstoke, Hampshire, UK : Scientific & Medical Division, Macmillan Press Ltd., c1991-
-
MeSH Terms:
-
Pregnancy Outcome*
Antiphospholipid Syndrome/*physiopathology
Pregnancy Complications/*physiopathology
Anticoagulants/administration & dosage ; Complement Activation ; Complement C3/metabolism ; Complement C4/metabolism ; Female ; Humans ; Pregnancy ; Pregnancy Complications/blood ; Pregnancy Complications/immunology ; Prognosis ; Risk Factors ; Thrombosis/drug therapy ; Thrombosis/etiology
-
Contributed Indexing:
-
Keywords: Anticardiolipin antibodies; antiphospholipid syndrome; complement; complement activation; lupus anticoagulant; pregnancy
-
Substance Nomenclature:
-
0 (Anticoagulants)
0 (Complement C3)
0 (Complement C4)
-
Entry Date(s):
-
Date Created: 20191019 Date Completed: 20200402 Latest Revision: 20200402
-
Update Code:
-
20240105
-
DOI:
-
10.1177/0961203319882507
-
PMID:
-
31623520
-
Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10-15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.